Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3981907 | 0.98 | GPBAR1 (0.57) | GPBAR1KMT2AGAAMEN1TSHR | |
| SCHEMBL27913634 | 0.89 | GPBAR1 (0.60) | GPBAR1KMT2AGAAMEN1TSHR | |
| SCHEMBL2475844 | 0.87 | GPBAR1 (0.59) | GPBAR1KMT2AGAAMEN1TSHR | |
| SCHEMBL3862966 | 0.87 | KMT2A (0.59) | GPBAR1KMT2AGAAMEN1TSHR | |
| SCHEMBL4718673 | 0.86 | KMT2A (0.72) | GPBAR1KMT2AGAAMEN1TSHR | |
| SCHEMBL3068021 | 0.86 | GPBAR1 (0.61) | GPBAR1KMT2AGAAMEN1TSHR | |
| SCHEMBL7769050 | 0.85 | KMT2A (0.58) | GPBAR1KMT2AGAAMEN1TSHR | |
| SCHEMBL12310938 | 0.85 | KMT2A (0.58) | GPBAR1KMT2AGAAMEN1TSHR | |
| SCHEMBL316093 | 0.85 | KMT2A (0.76) | GPBAR1KMT2AGAAMEN1TSHR | |
| Hydrochloric Acid SCHEMBL30684627 | 0.84 | KMT2A (0.70) | GPBAR1KMT2AGAAMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334301-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | University College Cardiff Consultants Limited (GB) | 2024-03-13 | — | — | EP | disclosed |
| CN-117279908-A | Heteroaryl compounds for the treatment of cognitive disorders | 加的夫大学学院咨询有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2022234271-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| CN-103889978-B | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | 霍夫曼-拉罗奇有限公司 | 2017-02-15 | — | — | CN | disclosed |
| EP-2768827-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-11-23 | — | — | EP | disclosed |
| EP-2768821-B1 | SOLID FORMS OF (1,1-DIOXO-4-THIOMORPHOLINYL)-[6-[[3-(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLYL]METHOXY]-3-PYRIDINYL]-METHANONE | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| US-8975397-B2 | Solid forms | HOFFMANN-LA ROCHE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| EP-2614052-B1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2014181287-A1 | HETEROCYCLYL COMPOUNDS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2014-11-13 | — | — | WO | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-7060710-B2 | Isoxazole pyrazoloindane derivatives as cognition enhancing GABAA α5 subtype ligands | MERCK SHARP & DOHME LTD. (GB) | 2006-06-13 | — | — | US | disclosed |
| US-6680319-B2 | TREATMENT OF OBSTRUCTIVE SYNDROMES OF THE LOWER URINARY TRACT, INCLUDING BENIGN PROSTATIC HYPERPLASIA, TREATMENT OF LOWER URINARY TRACT SYMPTOMS | RECORDATI S.A. (CH) | 2004-01-20 | — | — | US | disclosed |
| US-20040006226-A1 | Isoxazole pyrazoloindane derivatives as cognition enhancing GABA-A alpha 5 subtype ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-01-08 | — | — | US | disclosed |
| EP-1226131-B1 | ISOXAZOLECARBOXAMIDE DERIVATIVES | RECORDATI CHEM PHARM (IT) | 2003-12-17 | — | — | EP | disclosed |
| US-20020161012-A1 | Isoxazolecarboxamide derivatives | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-10-31 | — | — | US | disclosed |
| EP-1226131-A2 | ISOXAZOLECARBOXAMIDE DERIVATIVES | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-07-31 | — | — | EP | disclosed |
| US-6365591-B1 | FOR THERAPY OF OBSTRUCTIVE SYNDROMES OF THE LOWER URINARY TRACT, INCLUDING BENIGN PROSTATIC HYPERPLASIA (BPH), AND IN THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS (LUTS) AND NEUROGENIC LOWER URINARY TRACT DYSFUNCTION (NLUTD) | RECORDATI, S.A., CHEMICAL AND PHARMACUETICALS COMPANY (CH) | 2002-04-02 | — | — | US | disclosed |
| WO-2001029015-A2 | ISOXAZOLECARBOXAMIDE DERIVATIVES AS ALPHA1-ADRENERGIC RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | GPBAR1 2708/4885KMT2A 3283/4885GAA 1965/4885 |
| US-20020161012-A1 | Isoxazolecarboxamide derivatives | ADRA1D, NMUR1, NMUR2 | GPBAR1 703/4885KMT2A 1198/4885GAA 3666/4885 |
| US-20040006226-A1 | Isoxazole pyrazoloindane derivatives as cognition enhancing GABA-A alpha 5 subtype ligands | GABRA5, GABRB1, GABRA4 | GPBAR1 354/4885KMT2A 3319/4885GAA 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.